3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Philip Dutton of Solidatus, Benjamin Foster of Nurseify, and Tasos Katsaounis of Bread Man Baking Co. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from baking to software development — recently making headlines in Houston innovation.


Philip Dutton, CEO of Solidatus

Philip Dutton is the new Houston-based CEO of Solidatus, a London-founded data management startup. Photo via LinkedIn

As part of a company reorganization, data management startup Solidatus has established Houston as its North American headquarters and has named co-founder Philip Dutton as its Houston-based CEO.

Founded in London in 2017, Solidatus initially focused on supplying data management software to businesses in Europe, the Middle East, and Africa, but has since extended its reach to North America. Overall, Solidatus employs more than 110 people. It plans to triple its U.S. headcount over the next year.

“Solidatus serves visionary organizations that desire streamlined access and clarity of their data to build smarter and more profitable businesses. That’s everyone from Fortune 500 companies that have an unmanageably complex data landscape to startups and scale-ups that want to optimize their data practices from the get-go. There is no greater concentration of these organizations than in the U.S.,” Dutton, who had been the co-CEO, says in a news release. Click here to read more.

Benjamin Foster, founder and CEO of Nurseify

Benjamin Foster was leading human resources at Gulf Coast Division during Hurricane Harvey when he saw a huge need for an alternative to hiring short-term nurses quickly. That's when he had the idea for Nurseify, a platform that allows for nurses to find jobs — and for facilities to find nurses with the specialties they need. The platform is now live in five pilot states — Texas, Georgia, Florida, South Carolina, and Nevada.

Nurses are facing a significant amount of burnout — in part due to what they went through during the pandemic, but also because of the stressful work environments due to hiring misalignment. Foster says he's intentionally designed the platform to be supportive of nurses.

"We want Nurseify to be known as the most nurse-friendly company in the world. We believe we can bridge the gap between administration and operations and nurses," Foster says. "We want 'Nurseify' to become a verb at some point." Click here to read more.

Tasos Katsaounis, CEO and founder of Bread Man Baking Co.

How Tasos Katsaounis took his hobby and let it rise into a booming Houston business. Image via breadmanco.com

Four years ago, while looking to escape the daily rigors of his corporate work stress, Houstonian Tasos Katsaounis began to bake bread between Zoom calls. He took that hobby and turned it into Bread Man Baking Co. – a Houston-based artisan bread business that can now be tasted in restaurants all throughout the city.

“You know, there’s just something about the idea of growing something from nothing,” Katsaounis, CEO and founder of the company, tells InnovationMap. “I really feel like for the first time in my 26 years of working professionally, that I'm doing what I'm supposed to be doing and I'm super passionate about what I do every day.”

At the end of 2021, the company expanded from its 5,000-square-foot kitchen and moved its operations into a new 40,000-square-foot facility on the northeast side of Houston, close to the Budweiser and Kroger distribution buildings. At the time of the move, it had 17 employees and this year it has since grown to 42. Click here to read more.

How Tasos Katsaounis took his hobby and let it rise into a booming Houston business. Image via breadmanco.com

Houston entrepreneur on how he cooked up a new career

kneading a change

Four years ago, while looking to escape the daily rigors of his corporate work stress, Houstonian Tasos Katsaounis began to bake bread between Zoom calls.

And while for many during the pandemic it became somewhat of a cliché to bake sourdough at home, Katsaounis was getting a head start on developing the ingredients for Bread Man Baking Co. – a Houston-based artisan bread business that can now be tasted in restaurants all throughout the city.

“You know, there’s just something about the idea of growing something from nothing,” Katsaounis, CEO and founder of the company, tells InnovationMap. “I really feel like for the first time in my 26 years of working professionally, that I'm doing what I'm supposed to be doing and I'm super passionate about what I do every day.”

At the end of 2021, the company expanded from its 5,000-square-foot kitchen and moved its operations into a new 40,000-square-foot facility on the northeast side of Houston, close to the Budweiser and Kroger distribution buildings. At the time of the move, it had 17 employees and this year it has since grown to 42.

While in growth mode, Bread Man Baking Co. had to change its entire production process, investing in state-of-the-art industrial bakery equipment to allow them to produce at scale. The company now also uses cutting-edge breadmaking machinery to emulate Katsaounis’ Yiaya recipes from Greece to get the “hand shaping,” homemade effect in the dough.

They have also developed the capability of flash freezing their product to preserve the product’s integrity for distribution purposes without filling it with chemically based preservatives or conditioners that are traditionally used in the food industry.

“We are all about innovation and evolution, but it’s bread at the end of the day,” he says. “You have to look at it from the standpoint that there’s no way for us to triple our production and maintain quality and the integrity of an artisan bread product without innovating, without evolving, without adapting. We believe in the artisan process.”

Bread Man Baking Co. naturally ferments a majority of its products and bakes the bread in a stone deck, a traditional hearth oven with steam to obtain the coveted crusty bread that patrons desire.

The bread is sold in 65 restaurants around Houston – including Postino Wine Cafe's four locations, Georgia James, and the Tiny Boxwood concepts. The company is now also distributing to Whole Foods and H-E-B retailers, pushing out bread to five states total.

“We’ve done all this in the last six months since moving into our new facility,” he says. “It's been fun to watch. Every month is a new high sales month and we're just like, let’s keep this going.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston health tech innovator collaborates on promising medical device funded by DOD

team work

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect.

The team working on this new research seeks to minimize near-eventualities like blood clot formation, blood damage, and driveline complications such as infection and limitations in mobility. The four institutions will try to innovate with a device featuring new engineering designs, antithrombotic slippery hydrophilic coatings (SLIC), wireless power transfer systems, and magnetically levitated driving systems.

Wang and her team believe that the non-contact-bearing technology will help to decrease the risk of blood clotting and damage when implanting an LVAD. The IDEA Lab will test the efficacy and safety of the SLIC LVAD developed by the multi-institutional team with a lab-bench-based blood flow loop, but also in preclinical models.

“The Texas Heart Institute continues to be a leading center for innovation in mechanical circulatory support systems,” said Joseph G. Rogers, MD, the president and CEO of THI, in a press release.

“This award will further the development and testing of the SLIC LVAD, a device intended to provide an option for a vulnerable patient population and another tool in the armamentarium of the heart failure teams worldwide.”

If it works as hypothesized, the SLIC LVAD will improve upon current LVAD technology, which will boost quality of life for countless heart patients. But the innovation won’t stop there. Technologies that IDEA Lab is testing include wireless power transfer for medical devices and coatings to reduce blood clotting could find applications in many other technologies that could help patients live longer, healthier lives.

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."



An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

View All Listings